62 items matching your search terms.

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Nowak, A. K. Lesterhuis, W. J. Kok, P. S. Brown, C. Hughes, B. G. Karikios, D. J. John, T. Kao, S. C. Leslie, C. Cook, A. M. Pavlakis, N. Briscoe, K. O'Byrne, K. J. Karapetis, C. S. Lam, W. S. Langford, A. Yip, S. Stockler, M. R.
LANCET ONCOLOGY, 2020     DOI:10.1016/S1470-2045(20)30462-9

Enzalutamide with standard first-line therapy in metastatic prostate cancer

Davis, I. D. Martin, A. J. Stockler, M. R. Begbie, S. Chi, K. N. Chowdhury, S. Coskinas, X. Frydenberg, M. Hague, W. E. Horvath, L. G. Joshua, A. M. Lawrence, N. J. Marx, G. McCaffrey, J. McDermott, R. McJannett, M. North, S. A. Parnis, F. Parulekar, W. Pook, D. W. Reaume, M. N. Sandhu, S. K. Tan, A. Tan, T. H. Thomson, A. Tu, E. Vera-Badillo, F. Williams, S. G. Yip, S. Zhang, A. Y. Zielinski, R. R. Sweeney, C. J. Enzamet Trial Investigators the, Australian New Zealand, Urogenital Prostate Cancer Trials, Group
NEW ENGLAND JOURNAL OF MEDICINE, 2019     DOI:10.1056/NEJMoa1903835

Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: a subset analysis of the CABARET trial

Olafson, L. R. Siddell, A. H. Field, K. M. Byrnes, M. Rapkins, R. W. Ng, B. Nixdorf, S. Barnes, E. H. Johns, T. G. Yip, S. Simes, J. Nowak, A. K. Rosenthal, M. A. McDonald, K. L.
JOURNAL OF CLINICAL NEUROSCIENCE, 2019     DOI:10.1016/j.jocn.2019.08.044

Challenges of international oncology trial collaboration-a call to action

Tang, M. Joensuu, H. Simes, R. J. Price, T. J. Yip, S. Hague, W. Sjoquist, K. M. Zalcberg, J.
BRITISH JOURNAL OF CANCER, 2019     DOI:10.1038/s41416-019-0532-4

Protocol for the P3BEP trial (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

Lawrence, N. J. Chan, H. Toner, G. Stockler, M. R. Martin, A. Yip, S. Wong, N. Yeung, A. Mazhar, D. Pashankar, F. Frazier, L. McDermott, R. Walker, R. Tan, H. Davis, I. D. Grimison, P. Anzup,
BMC CANCER, 2018     DOI:10.1186/s12885-018-4745-3

A phase II trial of durvalumab (Medi 4736) in advanced endometrial cancer: PHAEDRA

Antill, YC. Stockler, M.R. Kok, P.S. Robledo, K.P. Gillies, K. Stark, J. Yip, S. Mileshkin, L. Australia New Zealand Gynaecological Oncology Group (ANZGOG),

Clinical utilization of targetable molecular results in pancreatic cancer: longer-term outcomes from the Individualized Molecular Pancreatic Cancer Therapy (IMPACT) trial

Chantrill, L.A. Nagrial, A. Johns, A. McKay, S. Gill, A.J. Pavlakis, N. Grimison, P.S. Asghari, G. Waddell, N. Chou, A. Chin, V.T. Sebastian, L.T. Verghis, J. Yip, S. Sjoquist, K.M. Simes, J. Biankin, A.

P3BEP (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

Grimison, P.S. Lawrence, N.J. Stockler, M.R. Martin, A.J. Yip, S. Wong, N. Yeung, A. Friedlander, M. Mazhar, D. Pashankar, F. Quinn, D.I. Walker, R. Winstanley, M. Hanning, F.J. Weickhardt, A.J. Stevanovic, A.G. Davis, I.D. Toner, G.C. Australian and New Zealand Urogenital and Prostate Cancer Trials Group,

AGITG NABNEC: a randomised phase II study of nab-paclitaxel in combination withcarboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas

Khasraw, M. Hofman, M. Chantrill, L. Pavlakis, N. Gebski, V. Gill, A. Markman, B. Yip, S. Gibbs, E. Karapetis, C. Wong, S.F. Rnasom, D. Michael, M. Wilson, K. Simes, J. Lipton, L.

AGITG NABNEC: a randomised phase II study of nab-paclitaxel in combination with carboplatin as first-line treatment of gastrointestinal neuroendocrine carcinomas

Khasraw, M. Lipton, L. Hofman, M. Gebski, V. Gill, A. Markman, B. Yip, S. Gibbs, E. Karapetis, C. Pavlakis, N. Wong, S.F. Ransom, D. Sjoquist, K. Michael, M. Rayani, U. Simes, J. Chantrill, L.

NIVORAD: a randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy

Mitchell, P. Siva, S. Kok, P.S. O'Byrne, K. Yeung, A. Livingstone, A. Donoghoe, M. Yip, S. Stockler, M.R. Australasian Lung Cancer Trials Group,

Integrate II: a randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer—an international study organized by the Australasian Gastrointestinal Trials Group

Sjoquist, K.M. Pavlakis, N. Martin, A.J. Tsobanis, E. Yip, S. Bang, Y.J. Alcindor, T. O'Callaghan, C.J. Shitara, K. Bekaii-Saab, T.S. Grothey, A. Chen, L.T. Simes, J. Zalcberg, R. Goldstein, D.

OSCILLATE: Phase 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation-positive advanced NSCLC

Solomon, B. Kok, P. S. Livingstone, A. Yip, S. Brown, C. Dawson, S.J. Wong, W. Pavlakis, N. Stockler, M.R.

Randomised phase III trial of enzalutamide in androgen deprivation therapy with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303)

Williams, S. Davis, I.D. Sweeney, C. Stockler, M.R. Martin, A.J. Hague, W. Coskinas, X. Yip, S. Tu, E. Lawrence, N.J. McDermott, R. Kelly, P.J. Deignan, O. Hughes, S. Fonteyne V. Tombal, B.L. Nguyen, P.L. Australian and New Zealand Urogenital and Prostate Cancer Trials Group,

P3BEP (ANZUP 1302): An international randomised phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

Wong, N. Mayar, N. Lawrence, N. Stockler, M Martin, M. Yip, S. Yeung, A. Friedlander, M. Mazhar, D. Pashankar, F. Quinn, D. Walker, R. Winstanley, M. Weickhardt, A Hanning, F Stevanovic, A. Davis, I. Toner, G, Grimison, P.